27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Celgene (NASDAQ: CELG) have been volatile since the company announced weak Phase III trial results for OTEZLA Wednesday morning.
The stock was trading in the red during the pre-market session, but has since rebounded. Wells Fargo and Deutsche Bank gave their opinions on the update.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Brian Abrahams is not very concerned about the trial results. According to Abrahams, missing the primary endpoint may have, “only an incremental negative effect.”
Abrahams further commented that this news items shouldn’t have a significant impact on the stock price.
Related: Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector
Robyn Karnauskas of Deutsche Bank is also not largely concerned about the test results.
“Signal may have been seen patients with early disease. But MRIs and radiographs need to be analyzed to further understand trend. Therefore, we can expect a reasonable delay in understanding the path forward with AS Co did see an efficacy signal in pre-specified subgroup of patients with early disease.”
Shares of Celgene were last trading 1.9 percent higher to $87.37.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.